Cowen and Company reissued their buy rating on shares of Sage Therapeutics Inc. (NASDAQ:SAGE) in a research report report published on Monday morning.

“SAGE presented posters with additional analysis of the ‘547 Ph1/2 data at the.”,” the firm’s analyst commented.

Several other equities analysts also recently commented on SAGE. Chardan Capital started coverage on shares of Sage Therapeutics in a report on Tuesday, May 24th. They set a sell rating and a $18.00 price target on the stock. Canaccord Genuity reiterated a buy rating on shares of Sage Therapeutics in a report on Friday, May 27th. Leerink Swann reiterated an outperform rating and set a $66.00 price target on shares of Sage Therapeutics in a report on Tuesday, June 21st. HC Wainwright started coverage on shares of Sage Therapeutics in a report on Thursday, June 23rd. They set a buy rating and a $56.00 price target on the stock. Finally, BMO Capital Markets started coverage on shares of Sage Therapeutics in a report on Tuesday, June 28th. They set an outperform rating and a $48.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $67.67.

Sage Therapeutics (NASDAQ:SAGE) opened at 45.98 on Monday. The stock’s market capitalization is $1.48 billion. The stock’s 50 day moving average is $39.53 and its 200 day moving average is $35.84. Sage Therapeutics has a 12-month low of $26.28 and a 12-month high of $62.64.

Sage Therapeutics (NASDAQ:SAGE) last announced its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by $0.06. Equities analysts predict that Sage Therapeutics will post ($4.38) earnings per share for the current fiscal year.

In other news, CFO Kimi Iguchi sold 2,500 shares of the stock in a transaction that occurred on Wednesday, September 7th. The shares were sold at an average price of $40.93, for a total transaction of $102,325.00. Following the transaction, the chief financial officer now directly owns 81,239 shares in the company, valued at $3,325,112.27. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Albert Robichaud sold 22,000 shares of the stock in a transaction that occurred on Tuesday, July 12th. The shares were sold at an average price of $40.00, for a total transaction of $880,000.00. Following the transaction, the insider now owns 140,222 shares in the company, valued at $5,608,880. The disclosure for this sale can be found here. Insiders own 5.60% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in SAGE. Legal & General Group Plc boosted its stake in Sage Therapeutics by 17.2% in the first quarter. Legal & General Group Plc now owns 4,146 shares of the biopharmaceutical company’s stock worth $134,000 after buying an additional 607 shares during the last quarter. Sphera Funds Management LTD. boosted its stake in Sage Therapeutics by 32.3% in the first quarter. Sphera Funds Management LTD. now owns 123,000 shares of the biopharmaceutical company’s stock worth $3,943,000 after buying an additional 30,000 shares during the last quarter. Granahan Investment Management Inc. MA boosted its stake in Sage Therapeutics by 77.2% in the first quarter. Granahan Investment Management Inc. MA now owns 486,985 shares of the biopharmaceutical company’s stock worth $15,613,000 after buying an additional 212,100 shares during the last quarter. Geode Capital Management LLC boosted its stake in Sage Therapeutics by 48.5% in the first quarter. Geode Capital Management LLC now owns 119,750 shares of the biopharmaceutical company’s stock worth $3,839,000 after buying an additional 39,100 shares during the last quarter. Finally, Pictet Asset Management Ltd. purchased a new stake in Sage Therapeutics during the first quarter worth approximately $1,214,000. Hedge funds and other institutional investors own 93.93% of the company’s stock.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. Its lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor.

5 Day Chart for NASDAQ:SAGE

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.